Basic Neuropsychopharmacology

Rutter's Child and Adolescent Psychiatry: Fifth Edition

Volumn , Issue , 2009, Pages 212-233

  Volkow, Nora ^a   Swanson, James ^b  

^a NATIONAL INSTITUTE ON DRUG ABUSE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Basic principles of clinical pharmacology; Effects of drugs on brain function and neural networks; Imaging studies of effects of drugs at their cellular targets; Imaging studies on distribution of drugs in human brain; Psychiatric disorders and psychotropic medications

Indexed keywords

EID: 69549155337     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9781444300895.ch16     Document Type: Chapter

References (143)

1. Abikoff, H., McGough, J., Vitiello, B., McCracken, J., Davies, M., Walkup, J., et al. for the RUPP Study Group. (2005). Sequential pharmacotherapy for children with comorbid attention-deficit/hyperactivity and anxiety disorders. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 418-427.
2. Alexander, G. E., Crutcher, M. D., & DeLong, M. R. (1990). Basal ganglia-thalamocortical circuits: parallel substrates for motor, oculomotor, "prefrontal" and "limbic" functions. Progress in Brain Research, 85, 119-146.
3. Allen, A. J., & Michelson, D. (2002). Drug development process for a product with a primary pediatric indication. Journal of Clinical Psychiatry, 63, 44-49.
4. Allen, A. J., Kurlan, R. M., Gilbert, D. L., Coffey, B. J., Linder, S. L., Lewis, D. W., et al. (2005). Atomoxetine treatment in children and adolescents with ADHD and comorbid tic disorders. Neurology, 65, 1941-1949.
5. Anders, T., & Sharfstein, S. (2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 2296-2298; author reply 2296-2298.
6. Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R., et al. (2005). Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology. Journal of Psychopharmacology, 19, 567-596.
7. Biederman, J., Quinn, D., Weiss, M., Markabi, S., Weidenman, M., Edson, K., et al. (2003). Efficacy and safety of Ritalin LA, a new, once daily, extended-release dosage form of methylphenidate, in children with attention deficit hyperactivity disorder. Paediatric Drugs, 5, 833-841.
8. Biederman, J., Swanson, J. M., Wigal, S. B., Kratochvil, C. J., Boellner, S. W., Earl, C. Q., et al. (2005). Efficacy and safety of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, flexible-dose study. Pediatrics, 116, e777-784.
9. Biederman, J., Swanson, J. M., Wigal, S. B., Boellner, S. W., Earl, C. Q., & Lopez, F. A. Modafinil ADHD Study Group. (2006). A comparison of once-daily and divided doses of modafinil in children with attention-deficit/hyperactivity disorder: a randomized, doubleblind, and placebo-controlled study. Journal of Clinical Psychiatry, 67(5), 727-735.
10. Bressan, R. A., Erlandsson, K., Jones, H. M., Mulligan, R., Flanagan, R. J., Ell, P. J., et al. (2003). Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? An in vivo quantitative [123I] epidepride SPET study of amisulpridetreated patients. American Journal of Psychiatry, 160, 1413-1420.
11. Buitelaar, J. K., Danckaerts, M., Gillberg, C., et al. for the Atomoxetine International Study Group. (2004). A prospective, multicenter, open-label assessment of atomoxetine in non-North American children and adolescents with ADHD. European Child and Adolescent Psychiatry, 13, 249-257.
12. Bymaster, F. P., Katner, J. S., Nelson, D. L., Hemrick-Luecke, S. K., Threlkeld, P. G., Heiligenstein, J. H., et al. (2002). Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat: a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology, 27, 699-711.
13. Centers for Disease Control and Prevention. (2005). Mental health in the United States. Prevalence of diagnosis and medication treatment for attention-deficit/hyperactivity disorder-United States, 2003. MMWR Morbidity and Mortality Weekly Report, 54, 842-847. Cephalon website. http://www.cephalon.com/.
14. Chan, Y. P., Swanson, J. M., Soldin, S. S., Thiessen, J. J., Macleod, S. M., Logan, W. (1983). Methylphenidate hydrochloride given with or before breakfast: II. Effects on plasma concentration of methylphenidate and ritalinic acid. Pediatrics, 72, 56-59.
15. Cheung, A. H., Emslie, G. J., & Mayes, T. L. (2006). The use of antidepressants to treat depression in children and adolescents. Canadian Medical Association Journal, 174, 193-200. Concerta website. http://www.concerta.net/Accessed March 2007.
16. Conners, C. K. (1966). The effect of dexedrine on rapid discrimination and motor control of hyperkinetic children under mild stress. Journal of Nervous and Mental Disease, 142, 429-433.
17. Correll, C. U., Penzner, J. B., Parikh, U. H., Mughal, T., Javet, T., Carbon, M., et al. (2006). Recognizing and monitoring adverse events of second-generation antipsychotics in children and adolescents. Child Adolescent Psychiatry Clinics North America, 15, 177-206.
18. Davis, J. M., Chen, N., & Glick, I. D. (2003). A meta-analysis of the efficacy of second-generation antipsychotics. Archives of General Psychiatry, 60, 553-564.
19. DeVeaugh-Geiss, J., March, J., Shapiro, M., Andreason, P. J., Emslie, G., Ford, L. M., et al. (2006). Child and adolescent psychopharmacology in the new millennium: a workshop for academia, industry, and government. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 261-270.
20. Emslie, G. J., Heiligenstein, J. H., Wagner, K. D., Hoog, S. L., Ernest, D. E., Brown, E., et al. (2002). Fluoxetine for acute treatment of depression in children and adolescents: a placebo-controlled, randomized clinical trial. Journal of the American Academy of Child and Adolescent Psychiatry, 41, 1205-1215.
21. Emslie, G. J., Hughes, C. W., Crismon M. L., Lopez, M., Pliszka, S., Toprac, M. G., et al. (2004). A feasibility study of the childhood depression medication algorithm: the Texas Children's Medication Algorithm Project (CMAP). Journal of the American Academy of Child and Adolescent Psychiatry, 43, 519-527.
22. Emslie, G. J., Rush, A. J., Weinberg, W. A., Kowatch, R. A., Hughes, C. W., Carmody, T., et al. (1997). A double-blind, randomized, placebo-controlled trial of fluoxetine in children and adolescents with depression. Archives of General Psychiatry, 54, 1031-1037.
23. Findling, R. L., Nucci, G., Piergies, A. A., Gomeni, R., Bartolic, E. I., Fong, R., et al. (2006). Multiple dose pharmacokinetics of paroxetine in children and adolescents with major depressive disorder or obsessive-compulsive disorder. Neuropsychopharmacology, 31, 1274-1285.
24. Fitzgerald, P. B., Kapur, S., Remington, G., Roy, P., & Zipursky, R. B. (2000). Predicting haloperidol occupancy of central dopamine D2 receptors from plasma levels. Psychopharmacology (Berlin), 149, 1-5.
25. Fleishaker, J., & Ferry, J. (1995). Pharmacokinetic-pharmacodynamic modeling in drug development: Comments and applications. In H. Derendorf, & F. Hochhaus (Eds.), Handbook of pharmacokinetic/pharmacodynamic correlation (pp. 57-78). Boca Raton: CRC Press.
26. Gabrielsson, J., & Weiner, D. (1997). Pharmacokinetic and pharmacodynamic data analysis, concepts and applications (2nd edn.). Stockholm: Swedish Pharmaceutical Press.
27. Gibbons, R. D., Hur, K., Bhaumik, D. K., & Mann, J. J. (2005). The relationship between antidepressant medication use and rate of suicide. Archives of General Psychiatry, 62, 165-172.
28. Gibson, A. P., Bettinger, T. L., Patel, N. C., & Crismon, M. L. (2006). Atomoxetine versus stimulants for treatment of attention deficit/hyperactivity disorder. Annals of Pharmacotherapy, 40, 1134-1142.
29. Gillberg, C., Melander, H., von Knorring, A. L., Janols, L. O., Thernlund, G., Hagglof, B., et al. (1997). Long-term stimulant treatment of children with attention-deficit hyperactivity disorder symptoms. A randomized, double-blind, placebo-controlled trial. Archives of General Psychiatry, 54, 857-864.
30. Glick, I. D., Murray, S. R., Vasudevan, P., Marder, S. R., & Hu, R. J. (2001). Treatment with atypical antipsychotics: new indications and new populations. Journal of Psychiatric Research, 35, 187-191.
31. Greenblatt, D. J., von Moltke, L. L., Harmatz, J. S., & Shader, R. I. (1998). Drug interactions with newer antidepressants: Role of human cytochromes P450. Journal of Clinical Psychiatry, 59 (Supplement 15), 19-27.
32. Greenhill, L., Beyer, D. H., Finkleson, J., Shaffer, D., Biederman, J., Conners, C. K., et al. (2002). Guidelines and algorithms for the use of methylphenidate in children with attention-deficit/hyperactivity disorder. Journal of Attention Disorders, 6(Supplement 1), S89-100.
33. Greenhill, L. L., Biederman, J., Boellner, S. W., Rugino, T. A., Sangal, R. B., Earl, C. Q., et al. (2006). A randomized, double-blind, placebo-controlled study of modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 503-511.
34. Greenhill, L. L., Pliszka, S., Dulcan, M. K., Bernet, W., Arnold, V., Beitchman, J., et al. (2001). Summary of the practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. Journal of the American Academy of Child and Adolescent Psychiatry, 40, 1352-1355.
35. Greenhill, L. L., Swanson, J. M., Steinhoff, K., Fried, J., Posner, K., Lerner, M., et al. (2003). A pharmacokinetic/pharmacodynamic study comparing a single morning dose of Adderall to twice-daily dosing in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 1234-1241.
36. Greenhill, L. L., Abikoff, H. B., Arnold, L. E., Cantwell, D. P., Connors, C. K., Elliott, G., et al. (1996). Medication treatment strategies in the MTA study: Relevance to clinicians and researchers. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 1304-1313.
37. Greenhill, L. L., Kollins, S., Abikoff, H., McCracker, J., Riddle, M., Swanton, J., et al. (2006). Efficacy and Safety of Immediate-Release Methylphemidate Treatment for Preschoolers with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry.
38. Grunder, G., Landvogt, C., Vernaleken, I., Buchholz, H. G., Ondracek, J., Siessmeier, T., et al. (2006). The striatal and extrastriatal D2/D3 receptor-binding profile of clozapine in patients with schizophrenia. Neuropsychopharmacology, 31, 1027-1035.
39. Gupta, S. K., Hwang, S. S., Benet, L. Z., & Gumbleton, M. (1993). Interpretation and utilization of effect and concentration data collected in an in vivo pharmacokinetic and in vitro pharmacodynamic study. Pharmaceutical Research, 10, 889-894.
40. Hardman, J. G., Limbird, P. B., Molinoff, P. B., Rutton, R. W., & Gilman, A. G. (Eds) Goodman & Gilman's The Pharmacological Basics of Therapeutics, Ninth Edition. New York: McGraw-Hill.
41. Hazell, P., O'Connell, D., Heathcote, D., Robertson, J., & Henry, D. (1995). Efficacy of tricyclic drugs in treating child and adolescent depression: a meta-analysis. British Medical Journal, 310, 897-901.
42. Health Canada. (2005). Health Canada suspends the market authorization of ADDERALL XR®, a drug prescribed for Attention Deficit Hyperactivity Disorder (ADHD) in children. Ottawa: Health Canada.
43. Hughes, C. W., Emslie, G. J., Crismon, M. L., Wagner, K. D., Birmaher, B., Geller, B., et al. (1999). The Texas Children's Medication Algorithm Project: report of the Texas Consensus Conference Panel on Medication Treatment of Childhood Major Depressive Disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 38, 1442-1454.
44. Jensen, P. S., Arnold, L. E., Swanson, J., Vitiello, B., Abikoff, H. B., Greenhill, L. L., et al. (2007). Follow-up of the NIMH MTA study at 36 months after randomization. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 988-1001.
45. Jick, H., Kaye, J. A., & Black, C. (2004). Incidence and prevalence of drug-treated attention deficit disorder among boys in the UK. British Journal of General Practice, 54, 345-347.
46. Kapur, S., Zipursky, R. B., & Remington, G. (1999). Clinical and theoretical implications of 5-HT2 and D2 receptor occupancy of clozapine, risperidone, and olanzapine in schizophrenia. American Journal of Psychiatry, 156, 286-293.
47. Kelsey, D. K., Sumner, C. R., Casat, C. D., Coury, D. L., Quintana, H., Saylor, K. E., et al. (2004). Once-daily atomoxetine treatment for children with attention-deficit/hyperactivity disorder, including an assessment of evening and morning behavior: A double-blind, placebo-contolled trial. Pediatrics, 114, 1-8.
48. Klein, D. F. (2006). The flawed basis for FDA post-marketing safety decisions: the example of anti-depressants and children. Neuropsychopharmacology, 31, 689-699.
49. Kratochvil, C. J., Newcorn, J. H., Arnold, L. E., Duesenberg, D., Emslie, G. J., Quintana, H., et al. (2005). Atomoxetine alone or combined with fluoxetine for treating ADHD with comorbid depressive or anxiety symptoms. Journal of the American Academy of Child and Adolescent Psychiatry, 44, 915-924.
50. Le Moal, M., & Simon, H. (1991). Mesocorticolimbic dopaminergic network: functional and regulatory roles. Physiological Reviews, 71, 155-234.
51. Leon, A. C., Marzuk, P. M., Tardiff, K., & Teres, J. J. (2004). Paroxetine, other antidepressants, and youth suicide in New York City: 1993 through 1998. Journal of Clinical Psychiatry, 65, 915-918.
52. Levy, G. (1994). Mechanism-based pharmacodynamic modeling. Clinical Pharmacology and Therapeutics, 56, 356-358.
53. Levy, G., Ebling, W., & Forrest, A. (1994). Concentration-or effectcontrolled clinical trails with sparse data. Clinical Pharmacology and Therapeutics, 56, 1-8.
54. Lewis, S. W., Davies, L., Jones, P. B., Barnes, T. R. E., Murray, R. M., Kerwin, R., et al. (2006). Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technology Assessment, 10, 1-165.
55. March, J., Silva, S., Petrycki, S., Curry, J., Wells, K., Fairbank, J., et al. (2004). Fluoxetine, cognitive-behavioral therapy, and their combination for adolescents with depression: Treatment for Adolescents With Depression Study (TADS) randomized controlled trial. Journal of the American Medical Association, 292, 807-820.
56. Marthi, K., Jakobsen, S., Bender, D., Hansen, S. B., Smith, S. B., Hermansen, F., et al. (2004). [N-methyl-11C] Mirtazapine for positron emission tomography neuroimaging of antidepressant actions in humans. Psychopharmacology (Berlin), 174, 260-265.
57. McCracken, J. T., Biederman, J., Greenhill, L. L., Swanson, J. M., McGough, J. J., Spencer, T. J., et al. (2003). Analog classroom assessment of a once-daily mixed amphetamine formulation, SLI381 (Adderall XR), in children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 673-683.
58. McDougle, C. J., Scahill, L., Aman, M. G., McCracken, J. T., Tierney, E., Davies, M., et al. (2005). Risperidone for the core symptom domains of autism: results from the study by the autism network of the research units on pediatric psychopharmacology. American Journal of Psychiatry, 162, 1142-1148.
59. McDougle, C. J., Scahill, L., McCracken, J. T., Aman, M. G., Tierney, E., Arnold, L. E., et al. (2000). Research Units on Pediatric Psychopharmacology (RUPP) Autism Network. Background and rationale for an initial controlled study of risperidone. Child and Adolescent Psychiatric Clinics of North America, 9, 201-224.
60. Medicines and Health Products Regulatory Agency. (2003). Selective Serotonin Reuptake Inhibitors (SSRIs): Overview of regulatory status and CSM advice relating to major depressive disorder (MDD) in children and adolescents including a summary of available safety and efficacy data. http://www.mhra.gov.uk/home/idcplg?IdcService=SS.
61. Meyer, J. H., Goulding, V. S., Wilson, A. A., Hussey, D., Christensen, B., Houle, S. (2002). Bupropion occupancy of the dopamine transporter is low during clinical treatment. Psychopharmacology (Berlin), 163, 102-105.
62. Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., et al. (2004). Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: An [11C] DASB positron emission tomography study. American Journal of Psychiatry, 161, 826-835.
63. Michelson, D., Faries, D., Wernicke, J., Kelsey, D., Kendrick, K., Sallee, F. R., et al. (2001). Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, dose-response study. Pediatrics, 108, E83.
64. Michelson, D., Adler, L., Spencer, T., Reimherr, F. W., West, S. W., Allen, A. J., et al. (2003). Atomoxetine in adults with ADHD: Two randomized, placebo-controlled studies. Biological Psychiatry, 53, 112-120.
65. Michelson, D., Read, H. A., Ruff, D. D., Witcher, J., Zhang, S., & McCracken, J. (2007). CYP2D6 and clinical response to atomoxetine in children and adolescents with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 46(2), 242-251.
66. Modi, N. B., Wang, B., Hu, W. T., & Gupta, S. K. (2000). Effect of food on the pharmacokinetics of osmotic controlled-release methylphenidate HCl in healthy subjects. Biopharmaceuticals and Drug Disposition, 21, 23-31.
67. Molina, B. S. G., Flory, K., Hinshaw, S. P., Greiner, A. R., Arnold, L. E., Swanson, J. et al. (2007). Deliquent behavior and emerging substance use in the MTA at 36 months: Prevalence, course, and treatment effects. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1027-1039.
68. MTA Cooperative Group. (1999a). A 14-month randomized clinical trial of treatment strategies for attention-deficit/hyperactivity disorder. The MTA Cooperative Group. Multimodal Treatment Study of Children with ADHD. Archives of General Psychiatry, 56, 1073-1086.
69. MTA Cooperative Group. (1999b). Moderators and mediators of treatment response for children with attention-deficit/hyperactivity disorder: the Multimodal Treatment Study of children with Attention-deficit/hyperactivity disorder. Archives of General Psychiatry, 56, 1088-1096.
70. MTA Cooperative Group. (2004a). National Insititute of Mental Health Multimodal Treatment Study of ADHD follow-up: 24-month outcomes of treatment strategies for attention-deficit/hyperactivity disorder (ADHD). Pediatrics, 113, 754-761.
71. MTA Cooperative Group. (2004b). National Institute of Mental Health Multimodal Treatment Study of ADHD follow-up: changes in effectiveness and growth after the end of treatment. Pediatrics, 113, 762-769.
72. National Institute of Mental Health. (2002). Medications. Bethesda: National Institutes of Health; p. 36. http://www.nimh.nih.gov/.
73. Neligan (undated) (http://www.4um.com/tutorial/science/pharmak.htm) National Institute for Health and Clinical Excellence (NICE). (2005).
74. Methylphenidate, atomoxetine and dexamfetamine for the treatment of attention deficit hyperactivity disorder in children and adolescents. http://www.nice.org.uk/page.aspx?o=TA013.
75. Nissen, S. E. (2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 1445-1448.
76. Pappadopulos, E., Macintyre, I. J. C., Crismon, M. L., Findling, R. L., Malone, R. P., Derivan, A., et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part II. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 145-161.
77. Peck, C. C. (1993). Concentration-controlled versus concentrationdefined clinical trials (reply) [Letter]. Clinical Pharmacology and Therapeutics, 53, 385-387.
78. Pliszka, S. R. (2005). The neuropsychopharmacology of attentiondeficit/hyperactivity disorder. Biological Psychiatry, 57, 1385-1390.
79. Pliszka, S. R., Matthews, T. L., Braslow, K. J., & Watson, M. A. (2006). Comparative effects of methylphenidate and mixed salts amphetamine on height and weight in children with attentiondeficit/hyperactivity disorder. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 520-526.
80. Popoli, M., Brunello, N., Perez, J., & Racagni, G. (2000). Second messenger-regulated protein kinases in the brain: their functional role and the action of antidepressant drugs. Journal of Neurochemistry, 74, 21-33.
81. Posner, M., & Raichle, M. (1994). Images of mind. New York: Scientific American Library.
82. Ranaldi, R., Pocock, D., Zereik, R., & Wise, R. A. (1999). Dopamine fluctuations in the nucleus accumbens during maintenance, extinction, and reinstatement of intravenous D-amphetamine selfadministration. Journal of Neuroscience, 19, 4102-4109.
83. Rappley, M. D., Moore, J. W., & Dokken, D. (2006). ADHD drugs and cardiovascular risk. New England Journal of Medicine, 354, 2296-2298; author reply 2296-2298.
84. Reynolds, G. P. (2004). Receptor mechanisms in the treatment of schizophrenia. Journal of Psychopharmacology, 18, 340-345.
85. Riddle, M. A., Geller, B., & Ryan, N. (1993). Another sudden death in a child treated with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 32, 792-797.
86. Santosh, P., Taylor, E., Swanson, J., Wigal, S., Chuang, S., Davies, M., et al. (2005). Refining the diagnoses of inattention and overactivity syndromes: a reanalysis of the Multimodal Treatment study of attention deficit hyperactivity disorder (ADHD) based on ICD-10 criteria for hyperkinetic disorder. Clinical Neuroscience Research, 5, 304-314.
87. Sauer, J., Ring, B. J., & Witcher, J. W. (2005). Clinical pharmacokinetics of atomoxetine. Clinical Pharmakokinetics, 44, 571-590.
88. Scahill, L., Koenig, K., Carroll, D. H., Patchler, M. (2007). Risperidone approved for the treatment of serious behavioral problems in children with autism. Journal of Child and Adolescent Psychiatry Nursing, 20, 188-190.
89. Schiffer, W. K., Volkow, N. D., Fowler, J. S., Alexoff, D. L., Logan, J., & Dewey, S. L. (2006). Therapeutic doses of amphetamine or methylphenidate differentially increase synaptic and extracellular dopamine. Synapse, 59, 243-251.
90. Schlyer, D. J., Volkow, N. D., Fowler, J. S., Wolf, A. P., Shiue, C. Y., Dewey, S. L., et al. (1992). Regional distribution and kinetics of haloperidol binding in human brain: a PET study with [18F] haloperidol. Synapse, 11, 10-19.
91. Schoemaker, R. C., van Gerven, J. M., & Cohen, A. F. (1998). Estimating potency for the Emax-model without attaining maximal effects. Journal of Pharmacokinetics and Biopharmaceutics, 26, 581-593.
92. Schur, S. B., Sikich, L., Findling, R. L., Malone, R. P., Crismon, M. L., Derivan, A., et al. (2003). Treatment recommendations for the use of antipsychotics for aggressive youth (TRAAY). Part I: a review. Journal of the American Academy of Child and Adolescent Psychiatry, 42, 132-144.
93. Seeman, P., & Tallerico, T. (1999). Rapid release of antipsychotic drugs from dopamine D2 receptors: an explanation for low receptor occupancy and early clinical relapse upon withdrawal of clozapine or quetiapine. American Journal of Psychiatry, 156, 876-884.
94. Seminowicz, D. A., Mayberg, H. S., McIntosh, A. R., Goldapple, K., Kennedy, S., Segal, Z., et al. (2004). Limbic-frontal circuitry in major depression: a path modeling meta-analysis. Neuroimage, 22, 409-418.
95. Shader, R. I., Harmatz, J. S., Oesterheld, J. R., Parmelee, D. X., Sallee, F. R., & Greenblatt, D. J. (1999). Population pharmacokinetics of methylphenidate in children with attention-deficit hyperactivity disorder. Journal of Clinical Pharmacology, 39, 775-785.
96. Shader, R. I., & Oesterheld, J. R. (2006). Facts and public policy: Should I keep my child on ADHD drugs? Journal of Clinical Pharmacology, 26, 223-224.
97. Shaw, P., Sporn, A., Gogtay, N., Overman, G. P., Greenstein, D., Gochman, P., et al. (2006). Childhood-onset schizophrenia: A double-blind, randomized clozapine-olanzapine comparison. Archives of General Psychiatry, 63, 721-730.
98. Shea, S., Turgay, A., Carroll, A., Schulz, M., Orlik, H., Smith, I., et al. (2004). Risperidone in the treatment of disruptive behavioral symptoms in children with autistic and other pervasive developmental disorders. Pediatrics, 114, e634-641.
99. Sheiner, L. B., Stanski, D. R., Vozeh, S., Miller, R. D., & Ham, J. (1979). Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine. Clinical Pharmacology and Therapeutics, 25, 358-371.
100. Solanto, M. V. (1998). Neuropsychopharmacological mechanisms of stimulant drug action in attention-deficit hyperactivity disorder: a review and integration. Behavioural Brain Research, 94(1), 127-152.
101. Spencer, E. K., & Campbell, M. (1994). Children with schizophrenia: diagnosis, phenomenology, and pharmacotherapy. Schizophrenia Bulletin, 20, 713-725.
102. Spencer, T., Biederman, J., Wilens, T., Harding, M., O'Donnell, D., & Griffin, S. (1996). Pharmacotherapy of attention-deficit hyperactivity disorder across the life cycle. Journal of the American Academy of Child and Adolescent Psychiatry, 35, 409-432.
103. Spencer, T. J., Biederman, J., Ciccone, P. E., Madras, B. K., Dougherty, D. D., Bonab, A. A., et al. (2006a). PET study examining pharmacokinetics, detection and likeability, and dopamine transporter receptor occupancy of short-and long-acting oral methylphenidate. American Journal of Psychiatry, 163, 387-395.
104. Spencer, T. J., Faraone, S. V., Biederman, J., Lerner, M., Cooper, K. M., & Zimmerman, B. (2006b). Does prolonged therapy with a long-acting stimulant suppress growth in children with ADHD? Journal of the American Academy of Child and Adolescent Psychiatry, 45, 527-537.
105. Steinhoff, K. W. (2004). Attention-deficit/hyperactivity disorder: Medication treatment-dosing and duration of action. American Journal of Managed Care, 10, S99-S109.
106. Swanson, J., Greenhill, L., Wigal, T., Kollins, S., Stehli, A., Davies, M., et al. (2006c). Stimulant-related reductions of growth rates in the PATS. Journal of the American Academy of Child and Adolescent Psychiatry. [epub].
107. Swanson, C. J., Perry, K. W., Koch-Krueger, S., Katner, J., Svensson, K. A., & Bymaster, F. P. (2006a). Effect of the attention deficit/hyperactivity disorder drug atomoxetine on extracellular concentrations of norepinephrine and dopamine in several brain regions of the rat. Neuropharmacology, 50, 755-760.
108. Swanson, J., Agler, D., Fineberg, E., Wigal, S., Flynn, D., Fineberg, K., et al. (1999b). University of California, Irvine, Laboratory School Protocol for Pharmacokinetic and Pharmacodynamic Studies. In L. Greenhill, & B. Osman (Eds.), Ritalin: Theory and practice (2nd edn.) (pp. 405-430). Mary Ann Liebert, Inc.
109. Swanson, J., Gupta, S., Guinta, D., Flynn, D., Agler, D., Lerner, M., et al. (1999a). Acute tolerance to methylphenidate in the treatment of attention deficit hyperactivity disorder in children. Clinical Pharmacology and Therapeutics, 66, 295-305.
110. Swanson, J., Gupta, S., Lam, A., Shoulson, I., Lerner, M., Modi, N., et al. (2003). Development of a new once-a-day formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Archives of General Psychiatry, 60, 204-211.
111. Swanson, J., McBurnett, K., Wigal, T., Pfiffner, L., Lerner, M., Williams, L., et al. (1993). Effect of stimulant medication on children with attention deficit disorder: A "Review of Reviews". Exceptional Children, 60, 154-162.
112. Swanson, J. M., Elliot, G. R., Greenhill, L. L., Wigal, T., et al. (2007a). Effects of stimulant medication on growth rates across 3 years in the MTA follow-up. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1304-1313.
113. Swanson, J. M., Greenhill, L. L., Lopez, F. A., Sedillo, A., Earl, C. Q., Jiang, J. G., et al. (2006b). Modafinil film-coated tablets in children and adolescents with attention-deficit/hyperactivity disorder: results of a randomized, double-blind, placebo-controlled, fixed-dose study followed by abrupt discontinuation. Journal of Clinical Psychiatry, 67, 137-147.
114. Swanson, J. M., Hinshaw, S. P., Arnold, L. E., Gibbons, R., et al. (2007b). Secondary evaluations of MTA 36-month outcomes: Propensity score and growth mixture model analyses. Journal of the American Academy of Child and Adolescent Psychiatry, 46, 1002-1013.
115. Tauscher, J., Hussain, T., Agid, O., Verhoeff, N. P. L. G., Wilson, A. A., Houle, S., et al. (2004). Equivalent occupancy of dopamine D1 and D2 receptors with clozapine: Differentiation from other atypical antipsychotics. American Journal of Psychiatry, 161, 1620-1625.
116. Tiihonen, J., Kuoppasalmi, K., Foer, J., Tuomola, P., Kuikanmaki, O., Vorma, H., et al. (2007). A comparison of aripiprazole, methyphenidate, and placebo for amphetamine dependence. American Journal of Psychiatry, 164, 160-162.
117. Troost, P. W., Steenhuis, M., Tuynman-Qua, H. G., Kalverdijk, L. J., Buitelaar, J. K., Minderaa, R. B., et al. (2006). Atomoxetine for attention-deficit/hyperactivity disorder symptoms in children with pervasive developmental disorders: A pilot study. Journal of Child and Adolescent Psychopharmacology, 16, 611-619.
118. US Food and Drug Administration. (2000). Center for Drug Evaluation and Research Approval Letter. In Alza Corporation, Final approval for Concerta Extended Release Tabs (pp. 21-121).
119. US Food and Drug Administration. (2003a). FDA approves Prozac for pediatric use to treat depression and OCD: FDA Talk Paper. Rockville: US Food and Drug Administration.
120. US Food and Drug Administration. (2003b). Reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). Public Health Advisory: US Food and Drug Administration.
121. US Food and Drug Administration. (2004a). Background information on the Suicidality Classification Project. US Food and Drug Administration.
122. US Food and Drug Administration. (2004b). Review of AERS data for marketed safety experience during stimulant therapy: death, sudden death, cardiovascular SAEs (including stroke). In M. D. Russell Katz (Ed.), Letter requesting assistance with analysis of AERS data for marketed safety experience with amphetamine and/or dextroamphetamine salts.
123. US Food and Drug Administration. (2005). In Alert for Healthcare Professionals: Adderall and Adderall XR (amphetamine). US Food and Drug Administration.
124. Vitiello, B. (2006). An update on publicly funded multisite trials in pediatric psychopharmacology. Child and Adolescent Psychiatric Clinics of North America, 15, 1-12.
125. Volkow, N. D., Ding, Y. S., Fowler, J. S., Wang, G. J., Logan, J., Gatley, J. S., et al. (1995). Is methylphenidate like cocaine? Studies on their pharmacokinetics and distribution in the human brain. Archives of General Psychiatry, 52, 456-463.
126. Volkow, N. D., Fowler, J. S., Wang, G. J., Dewey, S. L., Schlyer, D., MacGregor, R., et al. (1993). Reproducibility of repeated measures of carbon-11-raclopride binding in the human brain. Journal of Nuclear Medicine, 34, 609-613.
127. Volkow, N. D., & Swanson, J. M. (2003). Variables that affect the clinical use and abuse of methylphenidate in the treatment of ADHD. American Journal of Psychiatry, 160, 1909-1918.
128. Volkow, N. D., Wang, G. J., Fowler, J. S., Gatley, S. J., Logan, J., Ding, Y. S., et al. (1998). Dopamine transporter occupancies in the human brain induced by therapeutic doses of oral methylphenidate. American Journal of Psychiatry, 155, 1325-1331.
129. Volkow, N. D., Wang, G. J., Fowler, J. S., Logan, J., Franceschi, D., Maynard, L., et al. (2002). Relationship between blockade of dopamine transporters by oral methylphenidate and the increases in extracellular dopamine: therapeutic implications. Synapse, 43, 181-187.
130. Volkow, N. D., Wang, G. J., Fowler, J. S., Telang, F., Maynard, L., Logan, J., et al. (2004). Evidence that methylphenidate enhances the saliency of a mathematical task by increasing dopamine in the human brain. American Journal of Psychiatry, 161, 1173-1180.
131. Volkow, N. D., Wang, G. J., Ma, Y., Fowler, J. S., Wong, C., Jayne, M., et al. (2006). Effects of expectation on the brain metabolic responses to methylphenidate and to its placebo in non-drug abusing subjects. Neuroimage, 32(4), 1782-1992.
132. Wagner, K. D. (2005). Pharmacotherapy for major depression in children and adolescents. Progress in Neuropsychopharmacology and Biological Psychiatry, 29, 819-826.
133. Wagner, K. D., Ambrosini, P., Rynn, M., Wohlberg, C., Yang, R., Greenbaum, M. S., et al. (2003). Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. Journal of the American Medical Association, 290, 1033-1041.
134. Wagner, K. D., Robb, A. S., Findling, R. L., Jin, J., Gutierrez, M. M., & Heydorn, W. E. (2004). A randomized, placebo-controlled trial of citalopram for the treatment of major depression in children and adolescents. American Journal of Psychiatry, 161, 1079-1083.
135. Walkup, J., Labellarte, M., Riddle, M. A., Pine, D. S., Greenhill, L., Fairbanks, J., et al. for the RUPP Anxiety Study Group. (2002). Treatment of pediatric anxiety disorders: an open-label extension of the research units on pediatric psychopharmacology anxiety study. Journal of Child and Adolescent Psychopharmacology, 12, 175-188.
136. Wigal, S., McGough, J. J., McCracken, J. T., Biederman, J., Spencer, T. J., Posner, K. L., et al. (2005). A laboratory school comparison of mixed amphetamine salts extended release (Adderall XR) and atomoxetine (Strattera) in school-aged children with attention deficit/hyperactivity disorder. Journal of Attention Disorders, 9, 275-289.
137. Wigal, S., Sanchez, D., DeCory, H., D'Imperio, J., & Swanson, J. (2003). Selection of the optimal dose ratio for a controlleddelivery formulation of methylphenidate. Journal of Applied Research, 42, 1234-1241.
138. Wigal, T., Greenhill, L., Chuang, S., McGough, J., Vitiello, B., Skribala, A., et al. (2006). Safety and tolerability of methylphenidate in preschool children with ADHD. Journal of the American Academy of Child and Adolescent Psychiatry, 45, 1314-1322.
139. Wilens, T. (2004). Straight talk about psychiatric medications for kids (Revised edn.). New York: Guilford Press.
140. Wilens, T. E., Biederman, J., Baldessarini, R. J., Puopolo, P. R., & Flood, J. G. (1992). Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. Journal of the American Academy of Child and Adolescent Psychiatry, 31, 691-698.
141. Witcher, J. W., Long, A., Smith, B., Sauer, J. M., Heilgenstein, J., Wilens, T., et al. (2003). Atomoxetine pharmacokinetics in children and adolescents with attention deficit hyperactivity disorder. Journal of Child and Adolescent Psychopharmacology, 13, 53-63.
142. Zito, J. M., & Safer, D. J. (2005). Recent child pharmacoepidemiological findings. Journal of Child and Adolescent Psychopharmacology, 15, 5-9.
143. Zito, J. M., Tobi, H., de Jong-van den Berg, L. T., Fegert, J. M., Safer, D. J., Janhsen, K., et al. (2006). Antidepressant prevalence for youths: a multi-national comparison. Pharmacoepidemiology and Drug Safety, 15, 793-798.